Stop Funding Regulatory “Optimism.”

The MedTech equivalent of a code audit—independent FDA due diligence for Digital Health investors.

The Problem: The “Rose-Colored” Regulatory Gap

When VC and PE firms conduct technical due diligence, they hire experts to audit the code. But when it comes to regulatory strategy, most investors rely on founder self-reporting.

The reality? Digital health founders are systematically optimistic. They underestimate FDA timelines, overlook “de facto” medical device classifications, and ignore the looming shadow of warning-letter exposure.

If you’re betting $10M+ on a regulatory roadmap you haven’t independently verified, you aren’t investing—you’re gambling.

The Solution: Institutional-Grade FDA Readiness

We provide a high-velocity (1–2 week) regulatory due diligence report designed specifically for the deal cycle. We move at the speed of venture, providing the “Go/No-Go” clarity you need before the wire transfer.

“Think of us as your external Regulatory CTO. We don’t just read the pitch deck; we stress-test the legal and clinical assumptions that could kill your ROI.”

What We Clear Up

Our reports replace “founder vibes” with hard regulatory data. Every audit answers five critical questions: